A new peer-reviewed study published in JMIR Formative Research finds that social media drug advertising is directly influencing patients to request GLP-1 weight loss medications from their doctors — and that clinicians who offer both in-person and virtual care are fielding these requests most often. The findings raise important questions about how online advertising shapes medical decision-making.
What the Study Found
Researchers surveyed 98 medical students and clinicians about their experiences with patients requesting medications they had seen advertised on social media. The results pointed clearly to branded GLP-1 weight loss drugs as a leading category driving these requests. Respondents who provided both in-person and virtual care reported encountering these medication requests more frequently than those offering only one mode of care — suggesting that patients who use telehealth may have more exposure to, or comfort acting on, social media health advertising.
The study is notable because it captures perspectives from both practicing clinicians and medical students, offering a broad view of how prescription drug direct-to-consumer advertising on social platforms is filtering into the exam room.
Why This Matters for GLP-1 Patients
GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become among the most talked-about drugs on social media. Influencer posts, targeted ads, and viral before-and-after content have made these medications household names — and, according to this research, are motivating real conversations between patients and their providers.
That's not necessarily a bad thing. Patients who are well-informed and proactively ask about treatment options can have more productive appointments. However, the study highlights a concern shared across the medical community: social media ads don't always present the full clinical picture, including eligibility criteria, potential side effects, or cost considerations.
Key takeaway: Clinicians who see patients both in-person and virtually are reporting the highest rates of GLP-1 medication requests tied to social media advertising — a sign that online drug promotion is meaningfully influencing patient behavior across care settings.
What This Means If You're Considering a GLP-1 Drug
If you've seen ads for Ozempic, Wegovy, Mounjaro, or Zepbound on social media and are curious about whether one might be right for you, that curiosity is worth bringing to your doctor. However, keep a few things in mind:
- Social media ads are designed to be persuasive, not medically comprehensive.
- GLP-1 medications have specific approved indications — not everyone who wants one will qualify.
- Your prescriber can weigh your full health history in a way that no advertisement can.
What to Watch Next
This study adds to a growing body of research examining how direct-to-consumer drug advertising — especially on social platforms — affects prescribing patterns and patient expectations. As GLP-1 medications continue to dominate both medical and pop-culture conversations, regulators, healthcare systems, and pharmaceutical companies will likely face increasing scrutiny over how these drugs are marketed online. Further research with larger sample sizes will be needed to confirm and expand on these findings.
Frequently Asked Questions
If you're curious about whether a GLP-1 medication is appropriate for your health situation — regardless of where you first heard about it — the best next step is a conversation with your prescriber, who can evaluate your individual medical history, goals, and eligibility.
- Peer-reviewed journal article, 'Medical Students and Clinicians' Perceptions of Social Media Direct-to-Consumer Advertising and Medication Requests,' JMIR Formative Research, date not specified in source material.